Walleye Capital LLC Kal Vista Pharmaceuticals, Inc. Transaction History

Walleye Capital LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$11.07 - $16.04 $248,831 - $360,547	22,478 Added 22.98%	120,308 $1.43 Million
Q4 2023 Feb 14, 2024	BUY	$7.58 - $12.25 $299,046 - $483,287	39,452 Added 67.58%	97,830 $1.2 Million
Q3 2023 Nov 14, 2023	BUY	$8.95 - $11.35 $522,483 - $662,590	58,378 New	58,378 $562,000
Q4 2022 Feb 14, 2023	SELL	$4.2 - $14.24 $488,817 - $1.66 Million	-116,385 Reduced 78.18%	32,482 $219,000
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $546,389 - $933,576	-55,471 Reduced 27.15%	148,867 $2.16 Million
Q2 2022 Aug 08, 2022	BUY	$8.16 - $15.1 $1.14 Million - $2.12 Million	140,128 Added 218.23%	204,338 $2.01 Million
Q1 2022 May 16, 2022	BUY	$11.2 - $16.97 $719,152 - $1.09 Million	64,210 New	64,210 $946,000
Q3 2020 Nov 16, 2020	SELL	$9.83 - $13.99 $163,925 - $233,297	-16,676 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$6.75 - $12.89 $27,837 - $53,158	-4,124 Reduced 19.83%	16,676 $202,000
Q1 2020 May 15, 2020	BUY	$5.8 - $18.56 $120,640 - $386,048	20,800 New	20,800 $159,000

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $250M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.